Two Sigma Advisers LP Has $18.62 Million Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Two Sigma Advisers LP increased its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 14.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 664,100 shares of the medical device company's stock after buying an additional 84,700 shares during the quarter. Two Sigma Advisers LP owned about 1.36% of AtriCure worth $18,621,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Hood River Capital Management LLC bought a new stake in shares of AtriCure during the 2nd quarter worth about $40,422,000. First Light Asset Management LLC increased its stake in shares of AtriCure by 42.1% during the second quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company's stock valued at $44,736,000 after acquiring an additional 581,843 shares during the period. Millennium Management LLC raised its holdings in AtriCure by 132.5% during the second quarter. Millennium Management LLC now owns 952,765 shares of the medical device company's stock worth $21,694,000 after purchasing an additional 543,023 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in AtriCure by 151.6% in the third quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company's stock worth $6,425,000 after purchasing an additional 138,046 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in AtriCure by 31.5% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company's stock valued at $14,038,000 after purchasing an additional 119,929 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. UBS Group boosted their price objective on AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. StockNews.com raised shares of AtriCure from a "sell" rating to a "hold" rating in a report on Saturday, September 14th. Needham & Company LLC lifted their price objective on shares of AtriCure from $34.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. boosted their target price on shares of AtriCure from $30.00 to $40.00 and gave the stock an "overweight" rating in a report on Wednesday, October 30th. Finally, Canaccord Genuity Group raised their target price on shares of AtriCure from $53.00 to $61.00 and gave the stock a "buy" rating in a report on Monday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $42.00.

AtriCure Trading Down 0.9 %

Shares of ATRC stock traded down $0.31 during trading hours on Monday, reaching $33.94. 279,737 shares of the stock traded hands, compared to its average volume of 704,761. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.65 billion, a PE ratio of -40.99 and a beta of 1.40. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $39.04. The business has a fifty day moving average price of $32.39 and a 200 day moving average price of $26.88.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. The company had revenue of $115.91 million during the quarter, compared to analyst estimates of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The company's revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.20) earnings per share. On average, equities research analysts forecast that AtriCure, Inc. will post -0.72 EPS for the current year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.